Englander Institute for Precision Medicine

Publications

Found 10 results
Author Title Type [ Year(Asc)]
Filters: Author is Hensler, Michal  [Clear All Filters]
2024
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S et al..  2024.  Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.. Nat Commun. 15(1):2528.
2023
Holicek P, Truxova I, Rakova J, Salek C, Hensler M, Kovar M, Reinis M, Mikyskova R, Pasulka J, Vosahlikova S et al..  2023.  Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.. Cell Death Dis. 14(3):209.
2022
Fucikova J, Hensler M, Kasikova L, Lanickova T, Pasulka J, Rakova J, Drozenova J, Fredriksen T, Hraska M, Hrnciarova T et al..  2022.  An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.. Clin Cancer Res. 28(14):3053-3065.
2021
Yamazaki T, Wennerberg E, Hensler M, Buqué A, Kraynak J, Fucikova J, Zhou XKathy, Sveinbjørnsson B, Rekdal Ø, Demaria S et al..  2021.  LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells.. Oncoimmunology. 10(1):1962592.
Rakova J, Truxova I, Holicek P, Salek C, Hensler M, Kasikova L, Pasulka J, Holubova M, Kovar M, Lysak D et al..  2021.  TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients.. Oncoimmunology. 10(1):1889822.
2020
Truxova I, Kasikova L, Salek C, Hensler M, Lysak D, Holicek P, Bilkova P, Holubova M, Chen X, Mikyskova R et al..  2020.  Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.. Haematologica. 105(7):1868-1878.
Pilones KA, Hensler M, Daviaud C, Kraynak J, Fucikova J, Galluzzi L, Demaria S, Formenti SC.  2020.  Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.. Oncoimmunology. 9(1):1830524.
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):3819.
Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, Lanickova T, Pecen L, Truxova I, Vosahlikova S et al..  2020.  M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.. J Immunother Cancer. 8(2)
Buqué A, Bloy N, Perez-Lanzón M, Iribarren K, Humeau J, Pol JG, Levesque S, Mondragon L, Yamazaki T, Sato A et al..  2020.  Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer.. Nat Commun. 11(1):4787.